السوق العالمية للمضادات الحيوية الجليكوببتيدية - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL GLYCOPEPTIDE ANTIBIOTICS SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DRUG TREATMENT RATE BY MATURED MARKETS

5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.4 PATIENT FLOW DIAGRAM

5.5 KEY PRICING STRATEGIES

5.6 KEY PATIENT ENROLLMENT STRATEGIES

5.7 INTERVIEWS WITH SPECIALIST

5.8 OTHER KOL SNAPSHOTS

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATIENT TREATMENT SUCCESS RATES

7 MERGERS AND ACQUISITION

7.1 LICENSING

7.2 COMMERCIALIZATION AGREEMENTS

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLYCOPEPTIDE ANTIBIOTICS

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yest Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLYCOPEPTIDE ANTIBIOTICS

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OD THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.13.1 FORECAST MARKET OUTLOOK

10.13.2 CROSS COMPETITION

10.13.3 THERAPEUTIC PORTFOLIO

10.13.4 CURRENT DEVELOPMENT SCENARIO

11 MARKET ACCESS

11.1 10-YEAR MARKET FORECAST

11.2 CLINICAL TRIAL RECENT UPDATES

11.3 ANNUAL NEW FDA APPROVED DRUGS

11.4 DRUGS MANUFACTURER AND DEALS

11.5 MAJOR DRUG UPTAKE

11.6 CURRENT TREATMENT PRACTICES

11.7 IMPACT OF UPCOMING THERAPY

12 R & D ANALYSIS

12.1 COMPARATIVE ANALYSIS

12.2 DRUG DEVELOPMENTAL LANDSCAPE

12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

12.4 THERAPEUTIC ASSESSMENT

12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

13 MARKET OVERVIEW

13.1 DRIVERS

13.2 RESTRAINTS

13.3 OPPORTUNITIES

13.4 CHALLENGES

14 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY PRODUCT

14.1 OVERVIEW

14.2 FIRST-GENERATION GLYCOPEPTIDE ANTIBIOTICS

14.2.1 VANCOMYCIN

14.2.1.1. BRANDED

14.2.1.1.1. FIRVANQ

14.2.1.1.1.1 MARKET VALUE (USD MILLION)

14.2.1.1.1.2 MARKET VOLUME (UNITS)

14.2.1.1.1.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.2. VANCOCIN

14.2.1.1.2.1 MARKET VALUE (USD MILLION)

14.2.1.1.2.2 MARKET VOLUME (UNITS)

14.2.1.1.2.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.3. KABIMYCIN

14.2.1.1.3.1 MARKET VALUE (USD MILLION)

14.2.1.1.3.2 MARKET VOLUME (UNITS)

14.2.1.1.3.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.4. VANCORAY

14.2.1.1.4.1 MARKET VALUE (USD MILLION)

14.2.1.1.4.2 MARKET VOLUME (UNITS)

14.2.1.1.4.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.5. VANLID

14.2.1.1.5.1 MARKET VALUE (USD MILLION)

14.2.1.1.5.2 MARKET VOLUME (UNITS)

14.2.1.1.5.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.6. VANTOX

14.2.1.1.6.1 MARKET VALUE (USD MILLION)

14.2.1.1.6.2 MARKET VOLUME (UNITS)

14.2.1.1.6.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.7. VANCOTECH

14.2.1.1.7.1 MARKET VALUE (USD MILLION)

14.2.1.1.7.2 MARKET VOLUME (UNITS)

14.2.1.1.7.3 AVERAGE SELLING PRICE (USD)

14.2.1.1.8. OTHERS

14.2.1.2. GENERIC

14.2.2 TEICOPLANIN

14.2.2.1. BRANDED

14.2.2.1.1. TARGOCID

14.2.2.1.1.1 MARKET VALUE (USD MILLION)

14.2.2.1.1.2 MARKET VOLUME (UNITS)

14.2.2.1.1.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.2. TEICOX

14.2.2.1.2.1 MARKET VALUE (USD MILLION)

14.2.2.1.2.2 MARKET VOLUME (UNITS)

14.2.2.1.2.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.3. TEICOPLANINA RICHET

14.2.2.1.3.1 MARKET VALUE (USD MILLION)

14.2.2.1.3.2 MARKET VOLUME (UNITS)

14.2.2.1.3.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.4. TICOCIN

14.2.2.1.4.1 MARKET VALUE (USD MILLION)

14.2.2.1.4.2 MARKET VOLUME (UNITS)

14.2.2.1.4.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.5. FORPLUS

14.2.2.1.5.1 MARKET VALUE (USD MILLION)

14.2.2.1.5.2 MARKET VOLUME (UNITS)

14.2.2.1.5.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.6. T-PLANIN

14.2.2.1.6.1 MARKET VALUE (USD MILLION)

14.2.2.1.6.2 MARKET VOLUME (UNITS)

14.2.2.1.6.3 AVERAGE SELLING PRICE (USD)

14.2.2.1.7. OTHERS

14.2.2.2. GENERIC

14.3 SECOND-GENERATION SEMI-SYNTHETIC GLYCOPEPTIDE ANTIBIOTICS

14.3.1 ORITAVANCIN

14.3.1.1. BRANDED

14.3.1.1.1. KIMYRSA

14.3.1.1.1.1 MARKET VALUE (USD MILLION)

14.3.1.1.1.2 MARKET VOLUME (UNITS)

14.3.1.1.1.3 AVERAGE SELLING PRICE (USD)

14.3.1.1.2. ORBACTIV

14.3.1.1.2.1 MARKET VALUE (USD MILLION)

14.3.1.1.2.2 MARKET VOLUME (UNITS)

14.3.1.1.2.3 AVERAGE SELLING PRICE (USD)

14.3.2 TELAVANCIN

14.3.2.1. BRANDED

14.3.2.1.1. VIBATIV

14.3.2.1.1.1 MARKET VALUE (USD MILLION)

14.3.2.1.1.2 MARKET VOLUME (UNITS)

14.3.2.1.1.3 AVERAGE SELLING PRICE (USD)

14.3.3 DALBAVANCIN

14.3.3.1. BRANDED

14.3.3.1.1. DALVANCE

14.3.3.1.1.1 MARKET VALUE (USD MILLION)

14.3.3.1.1.2 MARKET VOLUME (UNITS)

14.3.3.1.1.3 AVERAGE SELLING PRICE (USD)

14.3.3.1.2. XYDALBA

14.3.3.1.2.1 MARKET VALUE (USD MILLION)

14.3.3.1.2.2 MARKET VOLUME (UNITS)

14.3.3.1.2.3 AVERAGE SELLING PRICE (USD)

15 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY INDICATION

15.1 OVERVIEW

15.2 BACTERIAL INFECTION

15.2.1 TEICOPLANIN

15.2.2 VAMCOMYCIN

15.3 ENDOCARDITIS

15.3.1 TEICOPLANIN

15.3.2 VAMCOMYCIN

15.4 PSEUDOMEMBRANOUS COLITIS

15.4.1 TEICOPLANIN

15.4.2 VAMCOMYCIN

15.5 ENTEROCOLITIS

15.5.1 TEICOPLANIN

15.5.2 VAMCOMYCIN

15.6 PNEUMONIA

15.6.1 TEICOPLANIN

15.6.2 VAMCOMYCIN

15.7 NOSOCOMIAL PNEUMONIA

15.7.1 TELAVANCIN

15.8 OSTEOMYELITIS

15.8.1 TEICOPLANIN

15.8.2 VAMCOMYCIN

15.9 SEPSIS

15.9.1 TEICOPLANIN

15.9.2 VAMCOMYCIN

15.1 MENINGITIS

15.10.1 TEICOPLANIN

15.10.2 VAMCOMYCIN

15.11 CNS INFECTION

15.11.1 TEICOPLANIN

15.11.2 VAMCOMYCIN

15.12 FEBRILE NEUTROPENIA

15.12.1 TEICOPLANIN

15.12.2 VAMCOMYCIN

15.13 INTRAABDOMINAL INFECTION

15.13.1 TEICOPLANIN

15.13.2 VAMCOMYCIN

15.14 PERITONITIS

15.14.1 TEICOPLANIN

15.14.2 VAMCOMYCIN

15.15 SHUNT INFECTION

15.15.1 TEICOPLANIN

15.15.2 VAMCOMYCIN

15.16 SURGICAL PROPHYLAXIS

15.16.1 TEICOPLANIN

15.16.2 VAMCOMYCIN

15.17 SKIN AND STRUCTURE INFECTION

15.17.1 TELAVANCIN

15.17.2 DALBAVANCIN

15.17.3 ORITAVANCIN

15.17.4 TEICOPLANIN

15.17.5 VAMCOMYCIN

15.18 CLOSTRIDIOIDES DIFFICILE INFECTION

15.18.1 TEICOPLANIN

15.18.2 VAMCOMYCIN

15.19 OTHERS

16 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

16.1 OVERVIEW

16.2 ORAL

16.2.1 CAPSULES

16.2.2 POWDERS

16.2.3 TABLETS

16.3 PARENTRAL

16.3.1 INTRAVENOUS

16.3.2 INTRAMUSCULAR

17 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DRUG TYPE

17.1 OVERVIEW

17.2 BRANDED

17.2.1 ORAL

17.2.1.1. CAPSULES

17.2.1.2. POWDERS

17.2.1.3. TABLETS

17.2.2 PARENTRAL

17.2.2.1. INTRAVENOUS

17.2.2.2. INTRAMUSCULAR

17.2.2.3. SUBCUTANEOUS

17.3 GENERIC

17.3.1 ORAL

17.3.1.1. CAPSULES

17.3.1.2. POWDERS

17.3.1.3. TABLETS

17.3.2 PARENTRAL

17.3.2.1. INTRAVENOUS

17.3.2.2. INTRAMUSCULAR

17.3.2.3. SUBCUTANEOUS

18 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY MODE OF PURCHASE

18.1 OVERVIEW

18.2 OVER THE COUNTER

18.3 PRESCRIPTION DRUGS

19 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY POPULATION TYPE

19.1 OVERVIEW

19.2 CHILDREN

19.3 ADULT

19.4 GERIATRIC

20 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY END USER

20.1 OVERVIEW

20.2 HOSPITAL

20.3 CLINICS

20.4 AMBULATORY CENTERS

20.5 SPECIALITY CLINICS

20.6 HOMECARE SETTINGS

20.7 OTHERS

21 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

21.1 OVERVIEW

21.2 DIRECT TENDER

21.3 RETAIL SALES

21.3.1 HOSPITAL PHARMACY

21.3.2 RETAIL PHARMACY

21.3.3 ONLINE PHARMACY

22 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, SWOT AND DBMR ANALYSIS

23 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, BY REGION

GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL GLYCOPEPTIDE ANTIBIOTICS MARKET, COMPANY PROFILE

25.1 ANI PHARMACEUTICALS, INC.

25.1.1 COMPANY OVERVIEW

25.1.2 REVENUE ANALYSIS

25.1.3 GEOGRAPHIC PRESENCE

25.1.4 PRODUCT PORTFOLIO

25.1.5 RECENT DEVELOPMENTS

25.2 MELINTA THERAPEUTICS LLC

25.2.1 COMPANY OVERVIEW

25.2.2 REVENUE ANALYSIS

25.2.3 GEOGRAPHIC PRESENCE

25.2.4 PRODUCT PORTFOLIO

25.2.5 RECENT DEVELOPMENTS

25.3 PFIZER INC.

25.3.1 COMPANY OVERVIEW

25.3.2 REVENUE ANALYSIS

25.3.3 GEOGRAPHIC PRESENCE

25.3.4 PRODUCT PORTFOLIO

25.3.5 RECENT DEVELOPMENTS

25.4 AZURITY PHARMACEUTICALS, INC.

25.4.1 COMPANY OVERVIEW

25.4.2 REVENUE ANALYSIS

25.4.3 GEOGRAPHIC PRESENCE

25.4.4 PRODUCT PORTFOLIO

25.4.5 RECENT DEVELOPMENTS

25.5 CUMBERLAND PHARMACEUTICALS INC.

25.5.1 COMPANY OVERVIEW

25.5.2 REVENUE ANALYSIS

25.5.3 GEOGRAPHIC PRESENCE

25.5.4 PRODUCT PORTFOLIO

25.5.5 RECENT DEVELOPMENTS

25.6 MYLAN N.V.

25.6.1 COMPANY OVERVIEW

25.6.2 REVENUE ANALYSIS

25.6.3 GEOGRAPHIC PRESENCE

25.6.4 PRODUCT PORTFOLIO

25.6.5 RECENT DEVELOPMENTS

25.7 FRESENIUS KABI INDIA PVT. LTD.

25.7.1 COMPANY OVERVIEW

25.7.2 REVENUE ANALYSIS

25.7.3 GEOGRAPHIC PRESENCE

25.7.4 PRODUCT PORTFOLIO

25.7.5 RECENT DEVELOPMENTS

25.8 AUROBINDO PHARMA.

25.8.1 COMPANY OVERVIEW

25.8.2 REVENUE ANALYSIS

25.8.3 GEOGRAPHIC PRESENCE

25.8.4 PRODUCT PORTFOLIO

25.8.5 RECENT DEVELOPMENTS

25.9 ABBVIE INC

25.9.1 COMPANY OVERVIEW

25.9.2 REVENUE ANALYSIS

25.9.3 GEOGRAPHIC PRESENCE

25.9.4 PRODUCT PORTFOLIO

25.9.5 RECENT DEVELOPMENTS

25.1 EILLY LILLY

25.10.1 COMPANY OVERVIEW

25.10.2 REVENUE ANALYSIS

25.10.3 GEOGRAPHIC PRESENCE

25.10.4 PRODUCT PORTFOLIO

25.10.5 RECENT DEVELOPMENTS

25.11 SANOFI AVENTIS S.P.A

25.11.1 COMPANY OVERVIEW

25.11.2 REVENUE ANALYSIS

25.11.3 GEOGRAPHIC PRESENCE

25.11.4 PRODUCT PORTFOLIO

25.11.5 RECENT DEVELOPMENTS

25.12 CIPLA INC.

25.12.1 COMPANY OVERVIEW

25.12.2 REVENUE ANALYSIS

25.12.3 GEOGRAPHIC PRESENCE

25.12.4 PRODUCT PORTFOLIO

25.12.5 RECENT DEVELOPMENTS

25.13 SAMARTH LIFE SCIENCES PVT. LTD.

25.13.1 COMPANY OVERVIEW

25.13.2 REVENUE ANALYSIS

25.13.3 GEOGRAPHIC PRESENCE

25.13.4 PRODUCT PORTFOLIO

25.13.5 RECENT DEVELOPMENTS

25.14 ALKEM LABS

25.14.1 COMPANY OVERVIEW

25.14.2 REVENUE ANALYSIS

25.14.3 GEOGRAPHIC PRESENCE

25.14.4 PRODUCT PORTFOLIO

25.14.5 RECENT DEVELOPMENTS

25.15 PANACEA BIOTEC

25.15.1 COMPANY OVERVIEW

25.15.2 REVENUE ANALYSIS

25.15.3 GEOGRAPHIC PRESENCE

25.15.4 PRODUCT PORTFOLIO

25.15.5 RECENT DEVELOPMENTS

25.16 PARKIN PHARMACEUTICALS

25.16.1 COMPANY OVERVIEW

25.16.2 REVENUE ANALYSIS

25.16.3 GEOGRAPHIC PRESENCE

25.16.4 PRODUCT PORTFOLIO

25.16.5 RECENT DEVELOPMENTS

25.17 ENDO PHARMACEUTICALS

25.17.1 COMPANY OVERVIEW

25.17.2 REVENUE ANALYSIS

25.17.3 GEOGRAPHIC PRESENCE

25.17.4 PRODUCT PORTFOLIO

25.17.5 RECENT DEVELOPMENTS

25.18 LABORATORIOS RICHMOND

25.18.1 COMPANY OVERVIEW

25.18.2 REVENUE ANALYSIS

25.18.3 GEOGRAPHIC PRESENCE

25.18.4 PRODUCT PORTFOLIO

25.18.5 RECENT DEVELOPMENTS

25.19 CRITICARE LABORATORIES PVT. LTD.

25.19.1 COMPANY OVERVIEW

25.19.2 REVENUE ANALYSIS

25.19.3 GEOGRAPHIC PRESENCE

25.19.4 PRODUCT PORTFOLIO

25.19.5 RECENT DEVELOPMENTS

25.2 ZUVENTUS HEALTHCARE.

25.20.1 COMPANY OVERVIEW

25.20.2 REVENUE ANALYSIS

25.20.3 GEOGRAPHIC PRESENCE

25.20.4 PRODUCT PORTFOLIO

25.20.5 RECENT DEVELOPMENTS

25.21 GLENMARK

25.21.1 COMPANY OVERVIEW

25.21.2 REVENUE ANALYSIS

25.21.3 GEOGRAPHIC PRESENCE

25.21.4 PRODUCT PORTFOLIO

25.21.5 RECENT DEVELOPMENTS

25.22 UNITED BIOTECH

25.22.1 COMPANY OVERVIEW

25.22.2 REVENUE ANALYSIS

25.22.3 GEOGRAPHIC PRESENCE

25.22.4 PRODUCT PORTFOLIO

25.22.5 RECENT DEVELOPMENTS

25.23 EMCURE PHARMACEUTICALS LTD.

25.23.1 COMPANY OVERVIEW

25.23.2 REVENUE ANALYSIS

25.23.3 GEOGRAPHIC PRESENCE

25.23.4 PRODUCT PORTFOLIO

25.23.5 RECENT DEVELOPMENTS

25.24 BAXTER.

25.24.1 COMPANY OVERVIEW

25.24.2 REVENUE ANALYSIS

25.24.3 GEOGRAPHIC PRESENCE

25.24.4 PRODUCT PORTFOLIO

25.24.5 RECENT DEVELOPMENTS

25.25 NEISS LABS PVT. LTD.

25.25.1 COMPANY OVERVIEW

25.25.2 REVENUE ANALYSIS

25.25.3 GEOGRAPHIC PRESENCE

25.25.4 PRODUCT PORTFOLIO

25.25.5 RECENT DEVELOPMENTS

25.26 CHANDRA BHAGAT PHARMA PVT. LTD.

25.26.1 COMPANY OVERVIEW

25.26.2 REVENUE ANALYSIS

25.26.3 GEOGRAPHIC PRESENCE

25.26.4 PRODUCT PORTFOLIO

25.26.5 RECENT DEVELOPMENTS

25.27 ASTRAZENECA PHARMA INDIA LTD.

25.27.1 COMPANY OVERVIEW

25.27.2 REVENUE ANALYSIS

25.27.3 GEOGRAPHIC PRESENCE

25.27.4 PRODUCT PORTFOLIO

25.27.5 RECENT DEVELOPMENTS

25.28 GSK

25.28.1 COMPANY OVERVIEW

25.28.2 REVENUE ANALYSIS

25.28.3 GEOGRAPHIC PRESENCE

25.28.4 PRODUCT PORTFOLIO

25.28.5 RECENT DEVELOPMENTS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH